BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22973056)

  • 1. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer.
    Wang L; Mosel AJ; Oakley GG; Peng A
    Mol Cancer Ther; 2012 Nov; 11(11):2401-9. PubMed ID: 22973056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
    Long X; Lin XJ
    J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squalene Inhibits ATM-Dependent Signaling in γIR-Induced DNA Damage Response through Induction of Wip1 Phosphatase.
    Tatewaki N; Konishi T; Nakajima Y; Nishida M; Saito M; Eitsuka T; Sakamaki T; Ikekawa N; Nishida H
    PLoS One; 2016; 11(1):e0147570. PubMed ID: 26824362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
    Brazina J; Svadlenka J; Macurek L; Andera L; Hodny Z; Bartek J; Hanzlikova H
    Cell Cycle; 2015; 14(3):375-87. PubMed ID: 25659035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
    Darlington Y; Nguyen TA; Moon SH; Herron A; Rao P; Zhu C; Lu X; Donehower LA
    Oncogene; 2012 Mar; 31(9):1155-65. PubMed ID: 21765465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
    Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
    Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
    Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
    J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1.
    Lin J; Zhang Q; Lu Y; Xue W; Xu Y; Zhu Y; Hu X
    PLoS One; 2014; 9(5):e98418. PubMed ID: 24846322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
    Zhang X; Wan G; Mlotshwa S; Vance V; Berger FG; Chen H; Lu X
    Cancer Res; 2010 Sep; 70(18):7176-86. PubMed ID: 20668064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
    Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
    Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wip1 phosphatase modulates ATM-dependent signaling pathways.
    Shreeram S; Demidov ON; Hee WK; Yamaguchi H; Onishi N; Kek C; Timofeev ON; Dudgeon C; Fornace AJ; Anderson CW; Minami Y; Appella E; Bulavin DV
    Mol Cell; 2006 Sep; 23(5):757-64. PubMed ID: 16949371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation.
    Choi DW; Na W; Kabir MH; Yi E; Kwon S; Yeom J; Ahn JW; Choi HH; Lee Y; Seo KW; Shin MK; Park SH; Yoo HY; Isono K; Koseki H; Kim ST; Lee C; Kwon YK; Choi CY
    Mol Cell; 2013 Aug; 51(3):374-85. PubMed ID: 23871434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.
    Sakai H; Fujigaki H; Mazur SJ; Appella E
    Cell Cycle; 2014; 13(6):1015-29. PubMed ID: 24552809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mathematical model of ATM/p53/NF- κB pathways points to the importance of the DDR switch-off mechanisms.
    Jonak K; Kurpas M; Szoltysek K; Janus P; Abramowicz A; Puszynski K
    BMC Syst Biol; 2016 Aug; 10(1):75. PubMed ID: 27526774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
    Jayachandran G; Ueda K; Wang B; Roth JA; Ji L
    PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance.
    Wansleben S; Davis E; Peres J; Prince S
    Cell Death Dis; 2013 Oct; 4(10):e846. PubMed ID: 24113180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
    Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
    BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.